Ortin Global Limited ORTINGLOBE NSEPHARMA
Company Overview
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
Recent Developments
- Mar 2026 Revenue of ₹10.05 L (-70.6% YoY); net profit ₹-74.04 L.
- Trailing 12 Months Year-on-year growth — revenue -59.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -74.4%, profit CAGR -230.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -74.44% |
| 1 Year: | -59.80% |
Compounded Profit Growth
| 5 Years: | -230.34% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +4.82% |
| 6 Months: | -5.83% |
| 3 Months: | -12.60% |
| 1 Month: | +3.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -74.4% CAGR over 5 years.
- Earnings shrank at -230.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORTINGLOBE Ortin Global Limited NSEPHARMA | 15.67 | -14.12 | ₹12.74 Cr | 0.00% | -32.17% | -59.85% | -74.44% | -230.34% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,895.00 | 37.64 | ₹4.55 L Cr | 0.85% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,315.00 | 84.60 | ₹2.47 L Cr | 0.31% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,914.00 | 78.62 | ₹1.87 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.23% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 688.00 | 237.24 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,156.90 | 23.10 | ₹1.16 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 33.25 | ₹1.12 L Cr | 0.94% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 90.86 | ₹99,417.45 Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 4.53 L | 3.98 L | 1.40 L | 1.23 L | 3.44 L |
| Cost of Revenue | - | 89,000 | 4.66 L | 2,000 | 1.44 L | 3.53 L |
| Gross Profit | - | 3.64 L | -68,000 | 1.38 L | -21,000 | -9,000 |
| Operating Expenses | - | 19.74 L | 15.57 L | 51.53 L | 4.74 L | 68,000 |
| Operating Income | - | -16.10 L | -16.25 L | -50.15 L | -4.95 L | -77,000 |
| EBITDA | - | -16.10 L | -16.25 L | -50.14 L | -4.94 L | -74,000 |
| Interest Expense | -1.46 L | 2,000 | 4,000 | 11,000 | - | 12,000 |
| Pretax Income | - | -16.12 L | -16.29 L | -50.26 L | -4.90 L | -89,000 |
| Tax Provision | - | 29,000 | 1.25 L | -1,000 | 42,000 | 4,000 |
| Net Income | - | -16.41 L | -17.54 L | -50.25 L | -5.32 L | -93,000 |
| Diluted EPS | - | -0.20 | -0.22 | -0.62 | -0.07 | -0.01 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 6.02 Cr | 2.11 Cr | 34.22 L | 10.05 L |
| Cost of Revenue | - | 3.39 Cr | 3.72 Cr | 21.46 L | 9.65 L |
| Gross Profit | - | 2.63 Cr | -1.60 Cr | 12.76 L | 40,000 |
| Operating Expenses | - | 2.36 Cr | 2.87 Cr | 98.16 L | 72.52 L |
| Operating Income | - | 27.06 L | -4.47 Cr | -85.40 L | -72.12 L |
| EBITDA | - | 48.47 L | -6.38 Cr | -82.31 L | -72.07 L |
| Interest Expense | - | 34.51 L | 46.28 L | 27,000 | 22,000 |
| Pretax Income | - | -11.05 L | -7.08 Cr | -83.75 L | -72.34 L |
| Tax Provision | - | -1.69 L | 96.58 L | 89,000 | 1.70 L |
| Net Income | - | -9.36 L | -8.04 Cr | -84.64 L | -74.04 L |
| Diluted EPS | - | -0.12 | -9.89 | -1.04 | -0.91 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 21.20 Cr | 6.66 Cr | 3.78 Cr | 4.65 Cr |
| Current Assets | - | 6.54 Cr | 6.34 Cr | 3.34 Cr | 3.84 Cr |
| Cash & Equivalents | - | 21.98 L | 45.93 L | 37.37 L | 60.59 L |
| Inventory | - | 2.60 Cr | 5.02 L | 1.98 L | 0 |
| Receivables | - | 3.42 Cr | 1.77 Cr | 26.12 L | 20.05 L |
| Total Liabilities | - | 10.33 Cr | 3.84 Cr | 1.80 Cr | 3.41 Cr |
| Current Liabilities | - | 6.98 Cr | 2.04 Cr | 1.55 Cr | 2.41 Cr |
| Long Term Debt | - | 2.96 Cr | 1.80 Cr | 25.00 L | 1.00 Cr |
| Total Debt | - | 6.45 Cr | 1.81 Cr | 25.00 L | 1.00 Cr |
| Total Equity | - | 10.86 Cr | 2.82 Cr | 1.98 Cr | 1.24 Cr |
| Shares Outstanding | - | 81.31 L | 81.31 L | 81.31 L | 81.31 L |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -25.33 L | -4.79 Cr | -41.03 L | -55.96 L |
| Investing Cash Flow | - | 82,000 | 12.00 Cr | -36,000 | 3.90 L |
| Financing Cash Flow | - | 90.40 L | -3.49 Cr | 32.83 L | 75.28 L |
| Capital Expenditure | -12.54 L | -20,000 | - | -36,000 | - |
| Free Cash Flow | - | -25.33 L | -4.79 Cr | -41.39 L | -55.96 L |
| Net Change in Cash | - | 65.89 L | 3.72 Cr | -8.56 L | 23.22 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 43.7% | -76.0% | 37.3% | 4.0% |
| Operating Margin % | - | 4.5% | -211.7% | -249.6% | -717.6% |
| Net Margin % | - | -1.6% | -380.8% | -247.3% | -736.7% |
| ROE % | - | -0.9% | -284.7% | -42.8% | -59.8% |
| ROCE % | - | 1.9% | -96.6% | -38.3% | -32.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ORTINGLOBE
ORTIN (ORTINGLOBE.NS) Stock: Moves 3.07% Down to ₹15.46 at the Close; Price Context: the ₹14.69 to ₹16.23 Range Remains in Focus in the Current Update - NHNL Divergence - siam.in
<a href="https://news.google.com/rss/articles/CBMiiwJBVV95cUxNR0lONDM1V0RJdVVHT1hwOGE2eXplMUw1ZUc5ZU9EaWd1aGIxa1d5MHl6ekh4Z3pobzVYUDA0Vzh0R3B4UmZmZ1FRUklWSXo5WHN6R2hOeGNYWVUwVVR6b1FHeFFFRXEzT0pLbGFweXlVNDBnaHpPam03ZHFFVVdfOWpHcl9rZ244T3l1SH…
Ortin Global Limited (ORTINGLOBE.NS) Faces Selling Pressure; Support at ₹16.15 in Focus - Catalyst Driven Stocks - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOOFplb25MX25FbEdNZjlnZEJCSjRHaHh5NnZBSjQxTjdxdlJXMzVjb09UTmtnTV9ncG1TLW9kOFpETlBqTFhoRUhvV3paOWlLX3JSOHNseTdCZWRVNjg5SkNpMDFqN3Y2NUlZTkN2Qjc5aHlKdi00bVZWYk1XZDdla3NTNEx5blBHX2t3eE…
ORTIN (ORTINGLOBE.NS) Shares: Ends Higher by 0.78% at ₹15.60 in Latest Trading; Immediate View: Support at ₹14.82 and Resistance at ₹16.38 Frame the Range in the Current Update - Dynamic Hedging - siam.in
<a href="https://news.google.com/rss/articles/CBMirgJBVV95cUxQWk1QNDU3a2kxR2RtMWlOSHJyV21xdVgxb0s0RnNxRjNQY3I4SkN0RXBLYllCbUhvcXBHQmhYLUI0WkVxYUVmNjlxNDlXdmNicEVMaDVZRUZORlIxNmlDb1RnQURDODhMZWFudlVHMEZWWUVxOG5DSi1lZHlxUUNhdno4b2VoWWFLZU9fYj…
ORTIN LABORATORIES Share Price - upstox.com
<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE1vT2RkN1o3SjlpUlNwcWVpVjNieER4VVk4dTZRWENGSjFBUnlDOEE0NVlWZ1ktcHlyWERXLUJSUUxrSHRfU2lSVUJuV1FZZGdOVldTc2NBOWJlamUtZFJQYmVRUjRxWjhGdGo4?oc=5" target="_blank">ORTIN LABORATORIES Shar…
ORTINGLOBE Q2 2025 Earnings: Sharp Revenue Decline and Net Loss Amid Challenging Environment - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNSFlvZ3hhblh0bEQ2VlRUVlhUM01OekhyQzByZ1ZwTnhSVzhfSW10Tm5LQ0FOdHQySWNHcmxuRk56dWdwR3VLM0N2emdUc0hTR2w4MDdjTS0xcFJwQWRrLTEwQ2w2MldFS1c2MDRrWHdiV21XcUhuSTNkZnh5b0MyZkd6MXB0OGZ4SGprbD…
ORTINGLOBE.NS Q2 2026 Earnings: Revenue Slumps 70.6% YoY, Net Loss at ₹0.91 per Share - Tangible Book Value - siam.in
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOem9oU0tuMmhrOWlrOXFXRWtsa0wzS1R3LWRidWVRZVpkY2IyOVlQV2lPYzYzT0JUZkJwNTd6Q2xFOExNdEVpYVlJcHRLS21jX3I4b1NlRC1hMkhYOGRSdWZpUW5oNm5QaVJhOGJMUk1CTVZNX1dxWDdORWZMMTJrbUc0R3dzWG4zOGFuZD…
ORTINGLOBE — Frequently Asked Questions
What is the current share price of Ortin Global Limited (ORTINGLOBE)?
As of 2026-09-20 09:43 IST, Ortin Global Limited (ORTINGLOBE) trades at ₹15.67 on NSE. Its 52-week range is ₹11.19 to ₹19.92.
What is the market capitalisation of ORTINGLOBE?
Ortin Global Limited (ORTINGLOBE) has a market capitalisation of ₹12.74 Cr on NSE.
What is the P/E ratio of ORTINGLOBE?
ORTINGLOBE trades at a trailing price-to-earnings (P/E) ratio of -14.12. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 11.68.
What is the return on equity (ROE) of ORTINGLOBE?
ORTINGLOBE has a return on equity (ROE) of -59.85%. Its return on capital employed (ROCE) is -32.17%.
Is ORTINGLOBE a good stock to buy?
This page provides a data-driven analysis of Ortin Global Limited (ORTINGLOBE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.